Bioelectric Eye Therapy Enters US Pivotal Trial for Dry AMD Vision Loss
A novel microcurrent device targeting retinal cells enters a major US clinical trial, offering potential hope for millions with dry AMD.
Summary
Dry age-related macular degeneration (AMD) has no widely effective treatment, but a new bioelectric therapy is now being tested in a major US clinical trial. i-Lumen Scientific's i-Lumen AMD System delivers low-level microcurrent through the eyelid to stimulate retinal pigment epithelium cells and improve photoreceptor function. The first US patient was enrolled at Texas Retina Associates in Fort Worth, Texas, joining an ongoing trial already underway in the UK. The i-SIGHT2 study is a randomized, sham-controlled pivotal trial evaluating both safety and effectiveness. Earlier feasibility data suggested improvements in visual function, retinal electrical activity, and structural biomarkers in treated eyes. The device remains investigational and has not yet received FDA approval.
Detailed Summary
Dry age-related macular degeneration is the leading cause of irreversible vision loss in older adults, yet effective treatments remain elusive. Most existing therapies target the wet form of AMD, leaving millions of patients with the more common dry form with few options. A new bioelectric approach is now entering a critical phase of clinical testing in the United States, offering a potentially non-invasive path to preserving or restoring vision in affected patients.
i-Lumen Scientific has enrolled its first US patient in the i-SIGHT2 pivotal study, a randomized and sham-controlled trial evaluating the i-Lumen AMD System. The therapy works by delivering low-level microcurrent stimulation through the eyelid. This is designed to boost transepithelial potential — essentially the electrical gradient across retinal tissue — and repolarize retinal pigment epithelium cells, which play a central role in supporting photoreceptor health and function.
The pivotal trial builds on earlier feasibility data from the i-SIGHT study, in which the company reported improvements across three domains in treated eyes: visual function, retinal electrophysiology, and structural biomarkers. These early signals are encouraging but come from a smaller, non-pivotal study and must be interpreted cautiously until confirmed in the current rigorous, controlled trial.
The i-SIGHT2 study is now active in both the United Kingdom and the United States, making it a global clinical program. The office-based administration of the therapy — delivered through the eyelid without surgery or injections — could be a significant practical advantage if proven effective, enabling broad clinical adoption.
Key caveats remain: the device is still investigational and lacks FDA or international regulatory approval. Pivotal trial results will take time, and patients should not expect near-term access. However, for the longevity-minded, preserving sensory function into old age is a critical and often overlooked pillar of healthspan, and this trial represents a meaningful step forward.
Key Findings
- First US patient enrolled in i-SIGHT2, a randomized sham-controlled pivotal trial for dry AMD bioelectric therapy.
- Device delivers low-level eyelid microcurrent to repolarize retinal pigment epithelium and support photoreceptor function.
- Prior feasibility study showed improvements in visual function, retinal electrophysiology, and structural biomarkers.
- Therapy is office-based and non-surgical, potentially enabling wide clinical use if approved.
- Device remains investigational with no FDA or regulatory approval yet granted.
Methodology
This is a news report based on a company press release from i-Lumen Scientific. Evidence is drawn from an ongoing pivotal trial and a prior feasibility study; peer-reviewed data from i-SIGHT2 are not yet available. Source credibility is moderate — Longevity.Technology is a recognized longevity media outlet, but independent verification of company claims is warranted.
Study Limitations
All efficacy claims currently rest on a smaller feasibility study, not the ongoing pivotal trial; results may not replicate at scale. The device has no regulatory approval and is not available outside the trial. Independent peer-reviewed publications on i-SIGHT feasibility data were not cited in the article and should be verified.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: